Collectively, these findings establish a fibroblast/CSF1R/RTK signaling axis that contributes to BPH pathogenesis and support the potential of RTK inhibition as a therapeutic strategy. The gene discussed is CSF1R; the disease is benign prostatic hyperplasia.